Simple answer as to why we have fallen in price Leon is many Australian companies recently have been attacked by shorters and we’re one of them.
Yes we slightly missed a couple of FY figures and signalled an increase in marketing but these were no biggies in themselves. At the time most analysts maintained their buy ratings.
However, shorters were able to take advantage of a three month window between FY results and AGM when they knew there would likely be a vacuum of info from the company. Accordingly, they took the opportunity to manufacture several negatives and circulate into the media including the idea Jayne would sell again because she doesn’t really believe in the companies prospects. The China / US trade war was going to negativity impact a2 sales. Marketing was being increased because revenues were slowing. Jayne is incompetent. New a2 competitors are going to stop a2 growing etc etc.
As it turned out, Jayne never sold, China / US trade war hasn’t effected a2, marketing has increased to increase revenue growth, new a2 competitors have come and gone (the latest local Chinese one is a joke) and Jayne is yet to be proved incompetent as we are yet to have any figures since new marketing strategy was established.
Clearly, the shorters have a motive for circulating their nonsense and have been proved to be very unreliable to date yet each time they just invent a new risk for more gullible people to believe.
which type of person are you?
me, I prefer facts and remain very suspicious of those with ulterior motives because they are usually liars.
All will be revealed at the AGM and I’ll continue to sleep very peacefully until then.
- Forums
- ASX - By Stock
- A2M
- High Risk Warning
High Risk Warning, page-88
-
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add A2M (ASX) to my watchlist
|
|||||
Last
$6.85 |
Change
-0.030(0.44%) |
Mkt cap ! $4.952B |
Open | High | Low | Value | Volume |
$6.93 | $6.98 | $6.83 | $10.27M | 1.490M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 18844 | $6.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.85 | 41602 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 11039 | 6.840 |
1 | 3000 | 6.830 |
4 | 17920 | 6.820 |
4 | 9541 | 6.810 |
2 | 5020 | 6.800 |
Price($) | Vol. | No. |
---|---|---|
6.850 | 41602 | 1 |
6.860 | 548 | 1 |
6.870 | 8050 | 3 |
6.880 | 16820 | 3 |
6.890 | 5115 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
A2M (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online